Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

YTHDF3 Modulates EGFR/ATK/ERK/p21 Signaling Axis to Promote Cancer Progression and Osimertinib Resistance of Glioblastoma Cells.

Anticancer research - 1 Dec 2023

Lee Hsun-Hua, Hsieh Ching-Chuan, Chang Cheng-Chih, Liao Wan-Ting, Chi Hsiang-Cheng

Abstract excerpt

BACKGROUND/AIM: Despite recent advances in EGFR-tyrosine kinase inhibitor (TKI) drugs for glioblastoma multiforme (GBM), intrinsic EGFR alterations in GBM have resulted in drug resistance and unsatisfactory clinical development of EGFR-TKIs. Determining the unknown mechanisms underlying EGFR-TKI drug resistance is an urgent, but unmet, medical need for GBM. Although several m6A RNA methylation regulators, such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Glioblastoma

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Source

Identifiers

PMID: 38030188
DOI: 10.21873/anticanres.16751

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

YTHDF3 Modulates EGFR/ATK/ERK/p21 Signaling Axis to Promote Cancer Progression and Osimertinib Resistance of Glioblastoma Cells.PMID 38030188Read ↗

PRMT6-mediated Transcriptional Activation of YTHDF2 Promotes Glioblastoma Migration, Invasion, and EMT via the Wnt–β-Catenin PathwaySemantic proximity Read ↗

A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastomaSemantic proximity Read ↗

METTL14-Mediated Bim mRNA m6A Modification Augments Osimertinib Sensitivity in EGFR-Mutant NSCLC Cells.Semantic proximity Read ↗

PRMT3-mediated arginine methylation of YBX1 promotes tumorigenesis in glioblastomaSemantic proximity Read ↗

The potential role of m6A reader YTHDF1 as diagnostic biomarker and the signaling pathways in tumorigenesis and metastasis in pan-cancerSemantic proximity Read ↗

The BRAF V600E/MEK/ERK/METTL3 positive feedback loop regulates autophagy and promotes stemness and invasiveness in glioblastoma via m6A modification.Semantic proximity Read ↗

PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transitionSemantic proximity Read ↗

YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell lineSemantic proximity Read ↗

Regulatory Mechanisms of STAT3 in GBM and its Impact on TMZ ResistanceSemantic proximity Read ↗

ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastomaSemantic proximity Read ↗

Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cellsSemantic proximity Read ↗

Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.